Approval · Notice of Compliance 26950 · 2021
PADCEV: Notice of Compliance 26950
Issued October 29, 2021
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 26950
- Date
- October 29, 2021
- Company
- Seagen Inc.
- Product type
- Biologic
- Submission
- New Drug Submission (NDS)
- Submission class
- Priority-NAS
Products in this notice
Medicinal ingredients
- ENFORTUMAB VEDOTIN 20 MG per VIAL
- ENFORTUMAB VEDOTIN 30 MG per VIAL